Dr. Rhonda Voskuhl Highlights Importance of Women’s Health Research in ABC7 News Segment | CleopatraRX

Dr. Rhonda Voskuhl Highlights Importance of Women’s Health Research in ABC7 News SegmentVon Greer2025-05-21T21:37:11+00:00

Dr. Rhonda Voskuhl Highlights Importance of Women’s Health Research in ABC7 News Segment

May 20, 2025

Dr. Rhonda Voskuhl, a leading expert in neuroimmunology and longtime advocate for women’s health research, appeared on ABC7 News to discuss the recent decision to restore funding to the Women’s Health Initiative (WHI), a landmark 30-year study of over 160,000 women.

In the segment, Dr. Voskuhl emphasized the critical role of the WHI in advancing women’s health research. She noted that the study has been instrumental in uncovering vital information on various health issues, including cancer, hormone therapy, chronic disease and aging. Dr. Voskuhl highlighted that the WHI’s findings have significantly influenced public health guidelines and clinical practices, leading to improved health outcomes for women nationwide.

Dr. Voskuhl also addressed concerns about the potential impact of funding cuts on ongoing research. She stressed the importance of sustained support for long-term studies like the WHI to ensure continued progress in understanding and addressing women’s unique health needs. “This is the way you make progress. You track..you find who’s the best population..you study when, how, and so forth..and then we’ll have new drugs hopefully that are coming up.”

Dr. Voskuhl notes that while some types of hormone therapy were found to increase breast cancer risk, others, including CleopatraRX’s own PearlPAK™ are showing new promise for potential benefits to the brain and other systems.

The full ABC7 News segment featuring Dr. Voskuhl can be viewed here:

https://abc7.com/post/trump-administration-promises-restore-funding-womens-health-initiative-30-year-study-outcry/16248198/

Back to Press Room

© Copyright 2025 CleopatraRX™. All Rights Reserved. View our Privacy Policy. and Terms and Conditions.

*PearlPAK™️ dose system is not intended to treat neurological diseases including dementia and Alzheimer’s Disease. It is specifically designed to target cognitive difficulties in perimenopause and early menopausal women only. If you are concerned about neurological disease or have a family history of neurological disease, contact your physician.

CleopatraRX™ and PearlPAK™ are trademarks of CleopatraRX Development, LLC. CleopatraRX™ is a service mark and is used throughout this website to represent the services offered by CleopatraRX Development, LLC. PearlPAK™ is a dosage product for use as a drug/routine system and/or treatment.

The PearlPAK™️ drug/routine system is protected by U.S. Patent No. 10,369,158 – PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY – which relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.

Estriol Therapy U.S. Patent No. 9,962,395 – COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION – Provides methods for reducing the progression of cognitive decline in a post-menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.

*PearlPAK™ dose system is not intended to treat neurological diseases including dementia and Alzheimer’s Disease. It is specifically designed to target cognitive difficulties in perimenopause and early menopausal women only. If you are concerned about neurological disease or have a family history of neurological disease, contact your physician.

CleopatraRX™ and PearlPAK™ are trademarks of CleopatraRX Development, LLC. CleopatraRX™ is a service mark and used throughout this website to represent the services offered by CleopatraRX Development, LLC. PearlPAK™ is a dosage product is for use as a drug/routine system and/or treatment.

The PearlPAK™ drug/routine system is protected by U.S. Patent No. 10,369,158 – PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY – which relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.

Estriol Therapy U.S. Patent No. 9,962,395 – COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION – Provides methods for reducing the progression of cognitive decline in a post – menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.